| Entry |
|
|---|
| Name |
Trifluoperazine hydrochloride (JAN/USP);
Stelazine (TN) |
|---|
| Product |
|
|---|
| Generic |
TRIFLUOPERAZINE HYDROCHLORIDE (Bryant Ranch Prepack), TRIFLUOPERAZINE HYDROCHLORIDE (Bryant Ranch Prepack), TRIFLUOPERAZINE HYDROCHLORIDE (Bryant Ranch Prepack), TRIFLUOPERAZINE HYDROCHLORIDE (Bryant Ranch Prepack), TRIFLUOPERAZINE HYDROCHLORIDE (Mylan Institutional), TRIFLUOPERAZINE HYDROCHLORIDE (Mylan Pharmaceuticals), TRIFLUOPERAZINE HYDROCHLORIDE (REMEDYREPACK), TRIFLUOPERAZINE HYDROCHLORIDE (REMEDYREPACK), TRIFLUOPERAZINE HYDROCHLORIDE (REMEDYREPACK), TRIFLUOPERAZINE HYDROCHLORIDE (Safecor Health LLC), TRIFLUOPERAZINE HYDROCHLORIDE (Sandoz) |
|---|
| Formula |
C21H24F3N3S. 2HCl
|
|---|
| Exact mass |
479.1177
|
|---|
| Mol weight |
480.42
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
|
|---|
| Remark |
| Product (DG00877): | D00799<US> |
|
|---|
| Efficacy |
Antipsychotic, Sedative-hypnotic, Dopamine D2 receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Phenothiazine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07029 | Antipsychotics - phenothiazines |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AB Phenothiazines with piperazine structure
N05AB06 Trifluoperazine
D00799 Trifluoperazine hydrochloride (JAN/USP) <US>
USP drug classification [BR:br08302]
Antipsychotics
1st Generation/Typical
Trifluoperazine
D00799 Trifluoperazine hydrochloride (JAN/USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00877 Trifluoperazine
D00799 Trifluoperazine hydrochloride
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
DG00877 Trifluoperazine
D00799 Trifluoperazine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00799 Trifluoperazine hydrochloride (JAN/USP) <US>
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00877 Trifluoperazine
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
DG00877 Trifluoperazine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 C8y C 20.9546 -18.6482
2 N1y N 22.1730 -17.9486
3 C8y C 20.9487 -20.0474
4 C8x C 19.7478 -17.9427
5 C8y C 23.3855 -18.6540
6 C1b C 22.1730 -16.5437
7 S2x S 22.1613 -20.7527
8 C8x C 19.7478 -20.7470
9 C8x C 18.5294 -18.6482
10 C8y C 23.3739 -20.0531
11 C8x C 24.5980 -17.9661
12 C1b C 23.3798 -15.8499
13 C8x C 18.5294 -20.0474
14 C8x C 24.5749 -20.7586
15 C8y C 25.8048 -18.6773
16 C1b C 23.3798 -14.4567
17 C8x C 25.8631 -20.0765
18 N1y N 24.5865 -13.7512
19 C1x C 25.7991 -14.4507
20 C1x C 24.5865 -12.3520
21 C1x C 27.0116 -13.7454
22 C1x C 25.7991 -11.6526
23 N1y N 27.0116 -12.3463
24 C1a C 28.2243 -11.6409
25 C1d C 27.0183 -17.9497
26 X F 28.2100 -17.2200
27 X F 27.7200 -19.1100
28 X F 26.3200 -16.7300
29 X Cl 31.6716 -18.2170
30 X Cl 31.6716 -18.2170
BOND 31
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 3 8 1
8 4 9 2
9 5 10 2
10 5 11 1
11 6 12 1
12 8 13 2
13 10 14 1
14 11 15 2
15 12 16 1
16 14 17 2
17 16 18 1
18 18 19 1
19 18 20 1
20 19 21 1
21 20 22 1
22 21 23 1
23 23 24 1
24 7 10 1
25 9 13 1
26 15 17 1
27 22 23 1
28 15 25 1
29 25 26 1
30 25 27 1
31 25 28 1
BRACKET 1 30.2400 -18.9000 30.2400 -17.2200
1 32.2700 -17.2200 32.2700 -18.9000
1 2
ORIGINAL 1 29
REPEAT 1 30
|
|---|
